Back to Search Start Over

Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ

Authors :
Ranjna Sharma
Charles E. Leonard
E. Shelley Hwang
Amy P. Sing
Faisal S. Vali
Adam I. Riker
Lauren E. Castellini
S. Chawla
Cornelia McCluskey
Lawrence J. Solin
Linna Li
William B. Farrar
Suzanne B. Evans
Lisa K. Jablon
Thomas G. Frazier
Abram Recht
Julia White
Dennis L. Carter
Benjamin Smith
study participants
Jennifer Manders
Eleftherios P. Mamounas
Henry Mark Kuerer
Daniel J. Buchholz
Ruixiao Lu
Study investigators
J. Michael Guenther
Lori Medeiros
Irene Wapnir
Anees B. Chagpar
Kathleen C. Horst
Source :
Annals of Surgical Oncology
Publisher :
Springer Nature

Abstract

Objective The aim of this study was to determine the impact of the results of the 12-gene DCIS Score assay on (i) radiotherapy recommendations for patients with pure ductal carcinoma in situ (DCIS) following breast-conserving surgery (BCS), and (ii) patient decisional conflict and state anxiety. Methods Thirteen sites across the US enrolled patients (March 2014–August 2015) with pure DCIS undergoing BCS. Prospectively collected data included clinicopathologic factors, physician estimates of local recurrence risk, DCIS Score results, and pre-/post-assay radiotherapy recommendations for each patient made by a surgeon and a radiation oncologist. Patients completed pre-/post-assay decisional conflict scale and state-trait anxiety inventory instruments. Results The analysis cohort included 127 patients: median age 60 years, 80 % postmenopausal, median size 8 mm (39 % ≤5 mm), 70 % grade 1/2, 88 % estrogen receptor-positive, 75 % progesterone receptor-positive, 54 % with comedo necrosis, and 18 % multifocal. Sixty-six percent of patients had low DCIS Score results, 20 % had intermediate DCIS Score results, and 14 % had high DCIS Score results; the median result was 21 (range 0–84). Pre-assay, surgeons and radiation oncologists recommended radiotherapy for 70.9 and 72.4 % of patients, respectively. Post-assay, 26.4 % of overall recommendations changed, including 30.7 and 22.0 % of recommendations by surgeons and radiation oncologists, respectively. Among patients with confirmed completed questionnaires (n = 32), decision conflict (p = 0.004) and state anxiety (p = 0.042) decreased significantly from pre- to post-assay. Conclusions Individualized risk estimates from the DCIS Score assay provide valuable information to physicians and patients. Post-assay, in response to DCIS Score results, surgeons changed treatment recommendations more often than radiation oncologists. Further investigation is needed to better understand how such treatment changes may affect clinical outcomes. Electronic supplementary material The online version of this article (doi:10.1245/s10434-016-5583-7) contains supplementary material, which is available to authorized users.

Details

Language :
English
ISSN :
10689265
Volume :
24
Issue :
3
Database :
OpenAIRE
Journal :
Annals of Surgical Oncology
Accession number :
edsair.doi.dedup.....2ce1a3f414f457af44b589d7b9c05727
Full Text :
https://doi.org/10.1245/s10434-016-5583-7